SELECTIVE HUMAN ESTROGEN-RECEPTOR ALPHA PARTIAL AGONIST TTC-352
Metastatic ER+ Breast Cancer
TTC Oncology, LLCSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
77 Active assets in the Metastatic ER+ Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAMOXIFEN Dana-Farber Cancer Institute | Phase 4 | BBB |
EXEMESTANE National Cancer Institute (NCI) | Phase 4 | BBB |
Everolimus UNC Lineberger Comprehensive Cancer Center | Phase 4 | BBB |
TAMOXIFEN Dana-Farber Cancer Institute | Phase 4 | BB |
Giredestrant Hoffmann-La Roche | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →